Background {#Sec1}
==========

Persistent Polyclonal Binucleated B-cell Lymphocytosis (PPBL) is characterized by a chronic, stable and asymptomatic lymphocytosis with binucleated lymphocytes \[[@CR1]\]. Binucleated lymphocytes are not specific for PPBL and can be observed in patients with multiple sclerosis treated by natalizumab \[[@CR2]\] or after accidental exposure to ionizing radiation. In the peripheral blood, a polyclonal increase of memory B cells (CD19^+^, CD5^−^, CD27^+^, IgM^+^, IgD^+^) is usually associated with a polyclonal increase in serum immunoglobulin-M (IgM) \[[@CR3]--[@CR6]\]. PPBL is characterized by a recurrent supernumerary isochromosome +i(3)(q10), a premature chromosome condensation (PCC) and a chromosomal instability \[[@CR3], [@CR4]\]. PPBL evolution is benign in most cases, but non-Hodgkin's lymphomas and solid tumors (pulmonary blastoma) were previously and rarely described \[[@CR7], [@CR8]\]. In this study, we report the follow-up and the cytogenetic characteristics of a large cohort of 150 PPBL patients. We report the occurrence of subsequent malignancies in up to 12 % of patients contrasting with previous studies. Strong association between supernumerary isochromosome 3q, chromosomal instability and PPBL led us to study more extensively the role of the long arm of chromosome 3 using SNP arrays in 10 patients. We observed that the *MECOM* gene, located on 3q26, was recurrently amplified in B-cells of PPBL patients.

Patients and methods {#Sec2}
====================

Patients {#Sec3}
--------

PPBL was diagnosed from the persistence during three months of binucleated lymphocytes on a peripheral blood film. Patients were included after written informed consent, in accordance with the Declaration of Helsinki and with institutional guidelines and after approval of the French relevant competent authorities and ethics committees (Committee of Protection of Individuals (CPP), Advisory Committee on the Processing of Information for Medical Research (CCTIRS) and the French National Commission for Data Protection (CNIL)).

Using multiparameter flow cytometry (MFC), B-cells were polyclonal in all cases, based on the expression of CD19 and the absence of a restriction of expression of light chain of immunoglobulin. Blood smears were reviewed in the same laboratory.

Conventional cytogenetic analysis (CCA) {#Sec4}
---------------------------------------

Blood samples were collected on heparin tubes at the time of diagnosis and during the follow-up. All samples were processed in the same laboratory. CCA was performed as previously described \[[@CR3]\]. As previously described \[[@CR9]\], chromosomal instability was defined as the gain and/or loss of whole chromosomes or chromosomal segments at a higher rate in tumor cell population compared to normal cells.

Fluorescent in situ hybridization (FISH) {#Sec5}
----------------------------------------

FISH was performed in order to detect supernumerary isochromosome +i(3)(q10) in metaphase and interphase cells using alpha-satellite chromosome 3 specific probes and Bcl6 (3q27) specific probes (Vysis™, USA). One hundred metaphases and three hundred interphases cells were analyzed per patient.

SNP array {#Sec6}
---------

SNP arrays were performed using Affymetrix™ Cytogenetics Whole-Genome 2.7M Arrays^®^ (Affymetrix™, USA). All samples were processed in the same laboratory. Patients were selected according to the availability of sufficient fresh cells (diagnosis) or frozen cells (follow-up). Immunomagnetic sorting was performed on whole blood samples or on thawed cells in order to purify CD19^+^ cells (Miltenyi™ AutoMACS Pro Separator^®^, Bergisch Gladbach, Germany). The two fractions (CD19^+^ positive and CD19^−^ negative selection) were kept and the purity was checked to be \>95 % by flow cytometry. The DNA was extracted from the two fractions using Gentra Puregene Blood Kit^®^ (Qiagen™, Hilden, Germany). Hybridization of the DNA on chips was performed according the manufacturer's instructions. Chips were analyzed using Affymetrix™ Chromosome Analysis Suite^®^ (ChASver 1.0.1). Database of annotations was NetAffx Build 30. Quality controls of the chips were set up according Affymetrix™ recommendations (SNP-QC ≥ 1.1 and MAPD (CN-QC) ≤ 0.27). Copy Number Aberrations (CNA) were called according user-defined thresholds (Copy Number (CN) markers \>50 and size \>25 kb). The Database of Genomic Variants (DGV, <http://projects.tcag.ca/variation/>) was consulted to determine whether CNA corresponded to genomic variants. Number and size of Copy Number Aberrations (CNAs) were analyzed and compared between patients and between CD19^+^ and CD19^−^ cells. CNA are called recurrent when at least two patients present the same CNA. Mosaicism phenomenon was detected in case of allele frequencies between disomic and trisomic states.

Results {#Sec7}
=======

PPBL was diagnosed in 150 untreated patients, whose main characteristics are described in Table [1](#Tab1){ref-type="table"}. Sixty-nine percent of cases showed an absolute lymphocytosis \>4 × 10^9^/L, with a mean percentage of binucleated lymphocytes at 3.9 % (1--40). Median follow-up was 60 months (1--402) and median overall survival was not reached. Eighteen patients (12 %) developed subsequent malignancies, among which nine cases were previously described (non Hodgkin's lymphomas (NHL) in three cases, solid tumors in two cases and monoclonal gammopathies of undetermined significance (MGUS) in 4 cases) \[[@CR10]\]. Among the 18 patients, six patients developed solid tumors with a mean time of occurrence of 87 months (3--156) (4 pulmonary cancers, 1 breast cancer and 1 cervical carcinoma). Twelve patients (8 %) developed hematological malignancies. Six cases of MGUS (IgM) (4 %) and NHL (4 %) occurred with a mean time of 75 months (0--264) and 58 months (0--120), respectively. Four patients developed a diffuse large B-cell lymphoma and 2 patients a splenic marginal zone lymphoma (Table [2](#Tab2){ref-type="table"} for details). Among these 18 cases, 17 patients were chronic smokers. These data strongly lead us to consider PPBL as a premalignant state requiring a long-term follow-up.Table 1Characteristics and follow-up of 150 patients with PPBLAge (years), Mean (min--max)40 (18.9--66.2)Sex (M/F)26 (17 %)/124 (83 %)Tobacco consumption130/145 (90 %)Clinical presentation Lymph node(s)10/108 (9 %) Splenomegaly19/106 (18 %) Hepatomegaly2/108 (2 %)Hemogram, Mean (min--max) White blood cells (10^9^/L)12.8 (7--44.8) Hemoglobin (g/dL)13.8 (10.1--16.9) Platelets (10^9^/L)228 (83--380) Lymphocytosis (10^9^/L)6.5 (2.2--41) Binucleated Lymphocytes (% of lymphocytes)3.9 (1--40)IgM (g/L), Mean (min--max)7.8 (2.17--20)HLA DR7 positive40/52 (77 %)Multiparameter Flow Cytometry---Mean (min--max) CD19 (%)50.4 (7--83)CytogeneticsDiagnosisFollow-up +i(3)(q10) positive by karyotype50/140 (36 %)20/32 (63 %) +i(3)(q10) positive by FISH80/128 (63 %)24/26 (92 %) PCC positive35/140 (25 %)8/32 (25 %) Chromosomal instability76/140 (54 %)31/32 (97 %)Subsequent Malignancies18/150 (12 %) MGUS6/150 (4 %) Non-Hodgkin's Lymphomas6/150 (4 %) Solid tumors6/150 (4 %)Clinical and biological data were collected from 27 centers. Median follow-up was 60 months (1--402) with unreached median overall survival*MGUS* monoclonal gammopathy of undetermined significanceTable 2Eighteen subsequent malignancies occurred in PPBL patientsPatientsDelay between PPBL and subsequent malignancy's diagnosisType of malignancyFollow-upUPN3638 monthsDLBCL56 monthsUPN4720 monthsSMZL+65 monthsUPN5792 monthsDLBCL99 monthsUPN63Diagnosis of PPBL and lymphoma was concomitantDLBCL+13 monthsUPN7177 monthsSMZL+86 monthsUPN83120 monthsDLBCL+131 monthsUPN1264 monthsMGUS+348 monthsUPN10144 monthsMGUS+148 monthsUPN15744 monthsMGUS+47 monthsUPN118Diagnosis of PPBL and MGUS was concomitantMGUS+36 monthsUPN163Diagnosis of PPBL and MGUS was concomitantMGUS+57 monthsUPN105Diagnosis of PPBL and MGUS was concomitantMGUS+42 monthsUPN596 monthsMammary carcinoma+272 monthsUPN63 monthsPulmonary carcinoma3 monthsUPN7022 monthsPulmonary carcinoma+22 monthsUPN86132 monthsPulmonary carcinoma+146 monthsUPN160114 monthsPulmonary carcinoma112 monthsUPN67156 monthsCervical carcinoma+181 monthsSix patients developed solid tumors (4 pulmonary cancers, 1 breast cancer and 1 cervical carcinoma) and 6 patients hematological malignancies (diffuse large B-cell lymphoma (DLBCL) in 4 cases, splenic marginal zone lymphoma (SMZL) in 2 cases) and 6 patients monoclonal gammopathies of undetermined significance (MGUS) (IgM)

At diagnosis, CCA and FISH were performed in 140 and 128 patients, respectively. During the follow-up, CCA was performed in 32 patients (21 %). CCA and FISH detected no cytogenetic abnormality in 52/140 patients (37 %). Recurrent supernumerary isochromosome +i(3)(q10) was identified in 82/140 patients (59 %). PCC, arising from asynchronous mitotic activity in multinucleated cells, was observed concomitantly with +i(3)(q10) in 30/140 patients (21 %). By CCA, trisomy 8 and del(6q) were also detected either as recurrent abnormalities (2/140 and 5/140, respectively) or as non-recurrent abnormalities (9/140 and 4/140, respectively). Chromosomal instability was observed in 76/140 patients (54 %) and persisted in 31/32 patients (97 %) during follow-up.

To determine whether 3q could be implicated in PPBL pathogenesis, SNP arrays were performed in 10 patients (3 males, 7 females) with +i(3)(q10) in 9/10 patients (Table [3](#Tab3){ref-type="table"} for details). Written informed consents were obtained from the patients. The comparative analysis of sorted CD19^+^ and CD19^−^ cells revealed that CNAs were observed predominantly in CD19^+^ B-cells on 3q (Table [4](#Tab4){ref-type="table"}) with mosaicism phenomenon in 3 patients. Genetic instability was observed in all cases and predominantly in CD19^+^ B-cells. We observed 143 recurrent CNAs with 129 gains (90 %) on 3q of B-cells (Table [5](#Tab5){ref-type="table"}). Interestingly, we identified with a high frequency (7/9 patients) partial or complete amplification of one particular genomic region located in 3q26.2. The size of this common minimal amplified region was 28 kilobases (85 copy number markers) located in coding region of *MECOM* gene (Fig. [1](#Fig1){ref-type="fig"}). This amplification was not detected in two patients (UPN147 and UPN136). In one of them (UPN147), no +i(3)(q10) was detected by CCA and/or FISH. Unfortunately, due to the mosaicism phenomenon, with less than 20 % of B-cells presenting +i(3)(q10), gain in *MECOM* gene has not been confirmed yet by other molecular studies, such as quantitative PCR.Table 3Characteristics of the 10 patients analyzed by SNP arrays (UPN: Unique Patient Number)PatientKaryotypePCC (%)FISH +i(3)(q10) (%)UPN8^b^46--47,XX, +i(3)(q10) \[3\] /46,XX,del(2)(q22), −17, +mar \[1\] /45, X, −X \[1\] /46,XX \[40\]AbsentPresent (6 %)UPN57^a^47,XY, +i(3)(q10) \[5\] /48,XY, +i(3)(q10), +12 \[01\]/46,XY,t(14;18)(q32;q22)\[01\]/47,XY,t(11;14)(q13;q32), +mar \[01\]/46,XY,add(3)(p26) \[1\] /47,XY, +22\[01\]/49,XY, +i(3)(q10), +8, +mar\[01\]/46,XY \[39\]AbsentPresent (7 %)UPN136^a^46,XX \[48\]/PCC \[2\]Present (4 %)Present (4 %)UPN71^c^47,XX, +X,del(6)(q15q26)\[01\]/46,XX,del(6)(q15q26),der(6)t(6;6)(q21;q23)\[08\]/46,XX,del(1)(q12),der(14)t(1;14)(p22;q32)\[02\]/46,XX\[09\]AbsentPresent (2 %)UPN127^b^47,XY, +i(3)(q10) \[3\] /46,X,der(Y)t(Y;?)(q12;?) \[3\] /46,XY \[12\]AbsentPresent (12 %)UPN138^a^46,XX,del(6)(q21q24) \[6\] /46,XX,der(8)t(3;8)(q11;q11),der(17)t(17;?)(p11;?) \[2\] /46,XX,del(17)(p11) \[2\] /46,XX,t(1;6)(q24;q21) \[1\] /46,XX,der(14)t(14;?)(p25;?) \[1\] /46,XX,dup(3)(p13p26) \[1\] /46,XX,der(4)t(4;?)(p16;?) \[1\] /46,XX \[26\]AbsentPresent (11 %)UPN99^a^47,XX, +18 \[2\] /47,XX, +3 \[1\] /46,XX \[37\]/PCC \[1\]Present (2 %)Present (4 %)UPN147^a^46,XX \[50\]AbsentAbsentUPN73^a^46,XX \[50\]AbsentPresent (1.4 %)UPN105^a^46,XY \[46\]/46,XY \[cp 4\]AbsentPresent (3 %)Depending on the quality of extracted DNA, we performed DNA arrays on ^a^both CD19^+^ and CD19^−^ cells in 7 patients, ^b^CD19^+^ cells in 2 patients and ^c^CD19^−^ cells in 1 patient. CCA and/or FISH detected +i(3)(q10) in 9/10 patients*PCC* premature chromosome condensationTable 4Repartition of CNAs observed in CD19^−^ and CD19^+^ cells. CD19^+^ cells presented twice as many CNAs as CD19^−^ \[83 CNAs (12--218) versus 42 (3--184)\]CD19−CNAs---Total (gains/losses)ChromosomeUPN73UPN71UPN57UPN136UPN138UPN99UPN147UPN105Mean12 (2/0)0 (0/0)4 (1/3)1 (0/1)3 (3/0)1 (0/1)0 (0/0)17 (0/17)3.5 (0.7/2.8)23 (1/2)1 (1/0)0 (0/0)2 (0/2)2 (2/0)0 (0/0)0 (0/0)24 (0/24)4.0 (0.5/3.5)32 (1/1)0 (0/0)3 (3/0)0 (0/0)0 (0/0)0 (0/0)0 (0/0)8 (1/7)1.6 (0.6/1.0)3p0 (0/0)0 (0/0)0 (0/0)0 (0/0)0 (0/0)0 (0/0)0 (0/0)0 (0/0)0.0 (0.0/0.0)*3q2 (1/1)0 (0/0)3 (3/0)0 (0/0)0 (0/0)0 (0/0)0 (0/0)8 (1/7)1.6 (0.6/1.0)*40 (0/0)0 (0/0)0 (0/0)2 (1/1)0 (0/0)0 (0/0)1 (1/0)30 (1/29)4.1 (0.4/3.7)50 (0/0)1 (0/1)1 (0/1)0 (0/0)1 (1/0)0 (0/0)0 (0/0)15 (0/15)2.3 (0.1/2.2)60 (0/0)0 (0/0)0 (0/0)0 (0/0)1 (1/0)0 (0/0)0 (0/0)11 (0/11)1.5 (0.1/1.4)70 (0/0)0 (0/0)0 (0/0)0 (0/0)1 (1/0)0 (0/0)1 (1/0)12 (0/12)1.8 (0.3/1.5)81 (0/1)0 (0/0)0 (0/0)1 (1/0)3 (3/0)0 (0/0)0 (0/0)6 (0/6)1.4 (0.5/0.9)90 (0/0)4 (0/4)3 (0/3)0 (0/0)4 (2/2)1 (1/0)0 (0/0)7 (0/7)2.4 (0.4/2.0)101 (1/0)1 (0/1)1 (0/1)0 (0/0)1 (1/0)0 (0/0)1 (1/0)7 (0/7)1.5 (0.4/1.1)110 (0/0)2 (1/1)0 (0/0)0 (0/0)2 (2/0)0 (0/0)1 (0/1)10 (0/10)1.9 (0.4/1.5)122 (2/0)0 (0/0)1 (0/1)0 (0/0)1 (1/0)0 (0/0)0 (0/0)8 (1/7)1.5 (0.5/1.0)130 (0/0)0 (0/0)2 (0/2)0 (0/0)1 (0/1)0 (0/0)0 (0/0)8 (1/7)1.4 (0.1/1.3)140 (0/0)0 (0/0)0 (0/0)0 (0/0)0 (0/0)0 (0/0)0 (0/0)6 (1/5)0.8 (0.1/0.7)152 (2/0)1 (1/0)1 (0/1)2 (0/2)2 (1/1)0 (0/0)1 (1/0)4 (1/3)1.6 (0.9/0.7)161 (1/0)0 (0/0)0 (0/0)1 (1/0)3 (1/2)0 (0/0)0 (0/0)1 (0/1)0.8 (0.4/0.4)170 (0/0)0 (0/0)1 (0/1)0 (0/0)1 (1/0)0 (0/0)0 (0/0)4 (2/2)0.8 (0.4/0.4)180 (0/0)0 (0/0)0 (0/0)0 (0/0)1 (1/0)0 (0/0)0 (0/0)1 (0/1)0.2 (0.2/0.1)190 (0/0)1 (0/1)0 (0/0)0 (0/0)0 (0/0)1 (0/1)1 (0/1)1 (0/1)0.5 (0.0/0.5)201 (1/0)0 (0/0)0 (0/0)0 (0/0)1 (1/0)0 (0/0)0 (0/0)0 (0/0)0.3 (0.3/0.0)211 (0/1)1 (0/1)1 (0/1)0 (0/0)0 (0/0)0 (0/0)0 (0/0)1 (0/1)0.5 (0.0/0.5)220 (0/0)0 (0/0)0 (0/0)0 (0/0)0 (0/0)0 (0/0)1 (1/0)1 (1/0)0.3 (0.3/0.0)X1 (1/0)7 (6/1)13 (13/0)1 (0/1)25 (24/1)0 (0/0)2 (1/1)1 (0/1)6.2 (5.6/0.6)Y1 (1/0)1 (1/0)2 (0/2)0 (0/0)2 (2/0)0 (0/0)0 (0/0)1 (0/1)0.9 (0.5/0.4)Total18 (13/5)20 (10/10)33 (18/15)10 (3/7)55 (48/7)3 (1/2)9 (6/3)184 (9/175)41.5 (13.5/28)CD19+CNAs---total (gains/losses)ChromosomeUPN73UPN8UPN57UPN136UPN127UPN138UPN99UPN147UPN105Mean120 (19/1)0 (0/0)0 (0/0)4 (0/4)0 (0/0)0 (0/0)5 (4/1)8 (1/7)0 (0/0)5.0 (3.6/1.4)222 (22/0)2 (1/1)0 (0/0)2 (0/2)0 (0/0)1 (0/1)3 (3/0)12 (1/11)0 (0/0)5.7 (3.9/1.8)320 (19/1)4 (4/0)26 (25/1)0 (0/0)46 (46/0)1 (1/0)2 (2/0)5 (0/5)113 (113/0)25.0 (24.2/0.8)3p11 (11/0)0 (0/0)1 (0/1)0 (0/0)0 (0/0)0 (0/0)0 (0/0)0 (0/0)0 (0/0)1.8 (1.7/0.1)*3q9 (8/1)4 (4/0)25 (25/0)0 (0/0)46 (46/0)1 (1/0)2 (2/0)5 (0/5)113 (113/0)23.2 (22.6/0.7)*49 (9/0)0 (0/0)2 (0/2)5 (1/4)0 (0/0)1 (1/0)0 (0/0)10 (1/9)0 (0/0)4.0 (2.3/1.7)514 (13/1)0 (0/0)0 (0/0)2 (0/2)0 (0/0)0 (0/0)0 (0/0)5 (0/5)1 (0/1)3.4 (2.4/1.0)610 (10/0)1 (1/0)0 (0/0)1 (0/1)0 (0/0)1 (1/0)1 (1/0)5 (1/4)0 (0/0)2.9 (2.3/0.6)712 (12/0)1 (0/1)0 (0/0)1 (0/1)1 (0/1)0 (0/0)1 (1/0)6 (1/5)0 (0/0)2.4 (1.6/0.8)813 (11/2)0 (0/0)0 (0/0)0 (0/0)0 (0/0)1 (0/1)1 (1/0)2 (0/2)0 (0/0)2.3 (1.8/0.5)914 (14/0)0 (0/0)0 (0/0)4 (0/4)0 (0/0)5 (0/5)1 (1/0)4 (1/3)0 (0/0)3.8 (2.4/1.4)108 (8/0)0 (0/0)0 (0/0)3 (0/3)0 (0/0)0 (0/0)0 (0/0)0 (0/0)0 (0/0)1.6 (1.2/0.4)119 (9/0)0 (0/0)0 (0/0)2 (0/2)0 (0/0)0 (0/0)1 (1/0)7 (0/7)0 (0/0)2.8 (1.8/1.0)125 (5/0)1 (0/1)2 (0/2)0 (0/0)1 (1/0)0 (0/0)1 (1/0)8 (1/7)0 (0/0)2.7 (1.6/1.1)134 (4/0)0 (0/0)1 (0/1)2 (0/2)0 (0/0)1 (0/1)0 (0/0)2 (0/2)1 (1/0)1.3 (0.7/0.6)143 (3/0)0 (0/0)1 (0/1)0 (0/0)0 (0/0)0 (0/0)2 (2/0)0 (0/0)0 (0/0)1.1 (1.0/0.1)155 (5/0)0 (0/0)1 (1/0)1 (0/1)2 (0/2)1 (0/1)0 (0/0)2 (1/1)1 (1/0)1.8 (1.2/0.6)162 (2/0)0 (0/0)0 (0/0)2 (0/2)1 (1/0)2 (0/2)0 (0/0)1 (1/0)1 (0/1)1.6 (1.0/0.6)174 (4/0)0 (0/0)0 (0/0)1 (0/1)1 (1/0)0 (0/0)0 (0/0)1 (1/0)0 (0/0)0.9 (0.8/0.1)185 (5/0)1 (1/0)0 (0/0)0 (0/0)0 (0/0)3 (3/0)1 (1/0)1 (0/1)0 (0/0)1.9 (1.8/0.1)191 (1/0)0 (0/0)0 (0/0)0 (0/0)1 (0/1)0 (0/0)0 (0/0)1 (0/1)0 (0/0)0.4 (0.2/0.2)205 (5/0)0 (0/0)0 (0/0)0 (0/0)0 (0/0)0 (0/0)2 (2/0)1 (1/0)0 (0/0)1.2 (1.2/0.0)211 (0/1)0 (0/0)0 (0/0)1 (0/1)0 (0/0)1 (0/1)0 (0/0)2 (0/2)0 (0/0)0.6 (0.0/0.6)220 (0/0)0 (0/0)0 (0/0)0 (0/0)0 (0/0)0 (0/0)0 (0/0)1 (1/0)0 (0/0)0.3 (0.3/0.0)X28 (27/1)1 (0/1)1 (1/0)7 (5/2)2 (2/0)5 (4/1)1 (1/0)5 (3/2)0 (0/0)7.0 (6.2/0.2)Y4 (4/0)1 (1/0)0 (0/0)6 (6/0)0 (0/0)14 (14/0)2 (2/0)0 (0/0)0 (0/0)3.0 (3.0/0.0)Total218 (211/7)12 (8/4)34 (27/7)44 (12/32)55 (51/4)37 (24/13)24 (23/1)89 (15/74)117 (115/2)82.7 (66.6/16.1)28 % of CNAs (0--97 %) were located on 3q in CD19^+^ cells compared to 5 % (0--11 %) in CD19^−^ cells (data not shown)Table 5Recurrent Copy Number Aberrations (CNA) in CD19^+^ B-cells. 143 CNA had been observedChrCytoregionRecurrenceRecurrence including mosaicismCN stateGeneMinimal common size (kbp)Genic region: total (T)\
Exonic (E)\
Intronic (I)CNA reported in DGV1p3322LossFAF131INo1p32.222GainC1orf16850.2E/INo2p23.222GainALK62E/IYes2q21.2--q21.322GainMGAT572E/INo3p24.222GainTHRB55.7INo3q11.223GainLOC25502550E/INo3q12.223GainABI3BP143E/IYes3q13.1323GainDZIP310.6INo3q13.3123GainZBTB2039INo3q13.3123GainGAP43399TNo3q13.3123GainLSAMP53INo3q13.3323GainTMEM39A176TNo3q13.3323GainKTELC1176TNo3q13.3323GainC3orf1176TNo3q13.3323GainCD80176TNo3q13.3323GainADPRH176TNo3q21.123GainHSPBAP1101E/INo3q21.124GainDIRC2101TNo3q21.124GainLOC100129550101TYes3q21.124GainSEC22A114TNo3q21.124GainPTPLB125TNo3q21.134GainMYLK70E/INo3q21.124GainCCDC14121E/IYes3q21.224GainKALRN169TNo3q21.224GainUMPS169TNo3q21.224GainZNF148164E/IYes3q21.224GainALDH1L1171E/INo3q21.334GainTXNRD3IT1299E/INo3q21.334GainCHCHD6299E/INo3q21.324GainKLHDC695TNo3q21.324GainRUVBL1211E/IYes3q21.324GainEEFSEC211E/IYes3q21.324GainGATA276E/IYes3q21.334GainLOC9024676TYes3q21.324GainC3orf27120.7TYes3q21.324GainTMCC1268TNo3q21.324GainCOL6A4P2131TYes3q22.124GainMRPL362E/IYes3q22.124GainSNORA5862TYes3q22.135GainCPNE446IYes3q22.124GainCPNE4155E/IYes3q22.124GainTMEM108120IYes3q22.124GainTOPBP169E/INo3q22.124GainRYK225TNo3q22.124GainANAPC13197TYes3q22.124GainCEP63197TYes3q22.224GainEPHB1144E/INo3q22.224GainPPP2R3A85E/INo3q22.324GainSOX14925TNo3q22.334GainCLDN18121TYes3q22.324GainARMC877E/IYes3q22.324GainTXNDC677E/IYes3q22.324GainESYT3202.7E/INo3q22.324GainCEP70202.7TNo3q22.324GainFAIM202.7TNo3q22.324GainPIK3CB202.7E/INo3q22.334GainLOC729627193TNo3q22.334GainLOC389151193TNo3q22.334GainFLJ46210193TNo3q22.334GainBPESC1193TNo3q22.324GainPISRT1319TNo3q2324GainMRPS2289E/INo3q2324GainCOPB289TNo3q2334GainNMNAT3277.8E/INo3q2345GainCLSTN246IYes3q2324GainTRIM42443TYes3q2324GainSLC25A36443TYes3q2424GainSLC9A9138E/IYes3q2424GainPLSCR447E/INo3q2424GainPLSCR569TNo3q2424GainAGTR1194E/INo3q25.124GainP2RY1374E/INo3q25.124GainMED12L74E/INo3q25.124GainP2RY1374TNo3q25.224GainSGEF364E/IYes3q25.2--q25.3134GainMME87.4E/INo3q25.3224GainVEPH178E/IYes3q25.3224GainC3orf5578E/INo3q25.3234GainMLF150E/INo3q26.124GainC3orf57120.6E/INo3q26.124GainOTOL1120.6TNo3q26.134GainSI747TNo3q26.134GainBCHE329E/INo3q26.124GainZBBX307TNo*3q26.267GainMDS128E/INo*3q26.224GainTERC59TYes3q26.224GainARPM159TYes3q26.224GainMYNN59TYes3q26.224GainLRRC3459E/IYes3q26.235GainTNIK31E/INo3q26.3124GainNLGN1125IYes3q26.3124GainNLGN164E/INo3q26.3124GainNAALADL2113E/IYes3q26.3224GainTBL1XR160E/INo3q26.3224GainKCNMB2121E/INo3q26.3324GainUSP1359E/INo3q26.3324GainPEX5L81E/INo3q26.3324GainCCDC39118E/IYes3q27.124GainYEATS2112E/INo3q27.124GainMAP6D1112TNo3q27.124GainPARL112E/INo3q27.224GainVPS8218E/INo3q27.224GainETV5157TNo3q27.224GainDGKG157E/INo3q27.324GainCRYGS110E/INo3q27.324GainTBCCD1110TNo3q27.324GainDNAJB11110TNo3q27.324GainAHSG110TYes3q27.324GainFETUB110E/IYes3q27.324GainST6GAL146E/IYes3q27.324GainMASP1428E/INo3q27.334GainRTP4148TNo3q27.324GainSST428TNo3q27.324GainFLJ42393191TYes3q2834GainLPP191E/IYes3q2824GainTP63142E/INo3q2824GainCLDN1203TNo3q2824GainCLDN16203TNo3q2824GainTMEM207203TNo3q2924GainC3orf59396E/INo3q2924GainMGC2889396TYes3q2924GainHRASLS396TYes3q2924GainATP13A5396E/INo3q2924GainATP13A4158E/IYes3q2924GainOPA1158TYes3q2924GainGP597E/INo3q2924GainATP13A397TYes3q2924GainTM4SF1987E/IYes3q2924GainUBXN787E/IYes3q2924GainDLG1240E/IYes3q2924GainFYTTD150TYes3q2924GainLRCH350E/IYes3q2924GainRPL35A91E/IYes3q2924GainIQCG91E/IYes3q2924GainLMLN91TYes4q13.322GainSLC4A446E/INo11p15.122GainNELL143INo14q13.122GainNPAS343IYes16p11.122GainLOC283914277TYes21p11.2--p11.123LossTPTE107TYesXp22.3333GainDHRSX31E/IYesXq1222GainEDA2R91E/IYesYq11.2122GainUSP9Y60E/INo129 gains concerned the long arm of chromosome 3 (3q). 123 gains concerned gene coding regions. 75 CNA did not include previously reported polymorphism (Database of Genomic Variants, DGV). Gain of one exon of *MDS1* (part of *MECOM* gene) was recurrently observed in 7 patients (including mosaicism phenomenon)*Chr* chromosome, *Recurrence* number of patients with the same CNA, *CN state* Copy Number state, gain or lossFig. 1Schematic representation of region 3q26.2 corresponding to *MECOM* gene in CD19^+^ B-cells of 9 patients. We observed a common minimal amplified region of 28 kilobases (85 copy number markers) in 7 patients. This amplification is observed in all the CD19^+^ B-cells in 6 patients (copy number at 3, CN 3) and in a part of CD19^+^ B-cells in 1 patient (copy number between 2 and 3 revealing a mosaicism phenomenon)

Discussion {#Sec8}
==========

Similar to the described link between aneuploidy, genetic instability and the development of human cancers \[[@CR11], [@CR12]\], supernumerary isochromosome 3q could be the cause of chromosomal instability observed in PPBL. Transfer of isochromosome 3q into myoblast cell line caused abnormal cytokinesis, centrosome amplification, aneuploidy and abolished G1 arrest following DNA damage. These observations might be related to an increasing expression of *ATR* gene located on 3q \[[@CR13]\]. Moreover, isochromosome 3q has been implicated in the progression of cervical carcinomas, where cells exhibiting either tetrasomy or aneusomy for chromosomes 3 and 17 increased significantly with disease progression \[[@CR13]--[@CR16]\]. Supernumerary isochromosome 3q could explain binucleated lymphocytes and chromosomal instability observed in PPBL. *MECOM* abnormalities, particularly the overexpression of *EVI1*, have been described in the pathogenesis of myeloid neoplasm such as acute myeloid leukemia and myelodysplastic syndrome, especially concerning cell-cycle disorders \[[@CR17]--[@CR21]\]. Furthermore, as observed by Stein et al., *EVI1* activation could lead to genetic instability \[[@CR22]\]. Even if it has never been observed in lymphoid neoplasm, the potential implication of *MECOM* in PPBL has to be elucidated.

The link between PPBL and subsequent malignancies remains unclear and the role of tobacco is probably dominant. Majority of our patients (17/18) with subsequent malignancies were chronic smokers. We reported recently a detailed description of 2 heavy smokers patients with subsequent malignancies, UPN57 and UPN71 \[[@CR23]\]. Tobacco use is a recognized risk factor in the development of solid tumor, such as pulmonary cancer, and also lymphoma \[[@CR24]\]. Therefore, in PPBL, where tobacco consumption is frequent (90 % of our cohort of 150 patients), smoking could represent a confounding factor in interpreting the link between PPBL and subsequent malignancies.

Isochromosome 3q has been described in cell-cycle deregulation, chromosomal instability and progression of cervical cancers. Our cytogenetic and clinical observations lead us to hypothesize that isochromosome 3q in B-cells plays a key role in the physiopathology and evolution of PPBL. Although isochromosome 3q has not been yet identified in tumor cells of subsequent malignancies \[[@CR23]\], it could be implicated in chromosomal and genomic instability. This genomic instability could be part of a multi-step process leading to the emergence of a malignant B lymphoproliferation. *MECOM* gene could be a good candidate to explain these observations and remains to be explored.
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